These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

848 related articles for article (PubMed ID: 35154086)

  • 1. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
    Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2021; 12():824728. PubMed ID: 35154086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Corzo C; Noriega MA; Sánchez-Cordón PJ; Labiod N; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2024; 15():1420304. PubMed ID: 39267752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2022; 13():995235. PubMed ID: 36172368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates.
    Pérez P; Albericio G; Astorgano D; Flores S; Sánchez-Corzo C; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2023; 14():1264323. PubMed ID: 38155964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.
    Bošnjak B; Odak I; Barros-Martins J; Sandrock I; Hammerschmidt SI; Permanyer M; Patzer GE; Greorgiev H; Gutierrez Jauregui R; Tscherne A; Schwarz JH; Kalodimou G; Ssebyatika G; Ciurkiewicz M; Willenzon S; Bubke A; Ristenpart J; Ritter C; Tuchel T; Meyer Zu Natrup C; Shin DL; Clever S; Limpinsel L; Baumgärtner W; Krey T; Volz A; Sutter G; Förster R
    Front Immunol; 2021; 12():772240. PubMed ID: 34858430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection.
    Liu R; Americo JL; Cotter CA; Earl PL; Erez N; Peng C; Moss B
    Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33688035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium.
    Marcos-Villar L; Perdiguero B; López-Bravo M; Zamora C; Sin L; Álvarez E; Sorzano CÓS; Sánchez-Cordón PJ; Casasnovas JM; Astorgano D; García-Arriaza J; Anthiya S; Borrajo ML; Lou G; Cuesta B; Franceschini L; Gelpí JL; Thielemans K; Sisteré-Oró M; Meyerhans A; García F; Esteban I; López-Bigas N; Plana M; Alonso MJ; Esteban M; Gómez CE
    Emerg Microbes Infect; 2024 Dec; 13(1):2387906. PubMed ID: 39087555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
    Americo JL; Cotter CA; Earl PL; Liu R; Moss B
    Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice.
    Zhu J; Wang Z; Li Y; Zhang Z; Ren S; Wang J; Xie S; Liao Z; Song B; Wu W; Yan F; Peng C
    J Virol; 2024 Jul; 98(7):e0052124. PubMed ID: 38874361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs.
    Routhu NK; Cheedarla N; Gangadhara S; Bollimpelli VS; Boddapati AK; Shiferaw A; Rahman SA; Sahoo A; Edara VV; Lai L; Floyd K; Wang S; Fischinger S; Atyeo C; Shin SA; Gumber S; Kirejczyk S; Cohen J; Jean SM; Wood JS; Connor-Stroud F; Stammen RL; Upadhyay AA; Pellegrini K; Montefiori D; Shi PY; Menachery VD; Alter G; Vanderford TH; Bosinger SE; Suthar MS; Amara RR
    Immunity; 2021 Mar; 54(3):542-556.e9. PubMed ID: 33631118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters.
    Boudewijns R; Pérez P; Lázaro-Frías A; Van Looveren D; Vercruysse T; Thibaut HJ; Weynand B; Coelmont L; Neyts J; Astorgano D; Montenegro D; Puentes E; Rodríguez E; Dallmeier K; Esteban M; García-Arriaza J
    Front Immunol; 2022; 13():845969. PubMed ID: 35371064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.
    Tscherne A; Schwarz JH; Rohde C; Kupke A; Kalodimou G; Limpinsel L; Okba NMA; Bošnjak B; Sandrock I; Odak I; Halwe S; Sauerhering L; Brosinski K; Liangliang N; Duell E; Jany S; Freudenstein A; Schmidt J; Werner A; Gellhorn Serra M; Klüver M; Guggemos W; Seilmaier M; Wendtner CM; Förster R; Haagmans BL; Becker S; Sutter G; Volz A
    Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34162739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.
    García-Arriaza J; Garaigorta U; Pérez P; Lázaro-Frías A; Zamora C; Gastaminza P; Del Fresno C; Casasnovas JM; Sorzano CÓS; Sancho D; Esteban M
    J Virol; 2021 Mar; 95(7):. PubMed ID: 33414159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters.
    Abdelnabi R; Pérez P; Astorgano D; Albericio G; Kerstens W; Thibaut HJ; Coelmont L; Weynand B; Labiod N; Delgado R; Montenegro D; Puentes E; Rodríguez E; Neyts J; Dallmeier K; Esteban M; García-Arriaza J
    Front Immunol; 2023; 14():1163159. PubMed ID: 37920464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
    He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
    Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.
    Nambulli S; Escriou N; Rennick LJ; Demers MJ; Tilston-Lunel NL; McElroy AK; Barbeau DJ; Crossland NA; Hoehl RM; Schrauf S; White AG; Borish HJ; Tomko JA; Frye LJ; Scanga CA; Flynn JL; Martin A; Gerke C; Hartman AL; Duprex WP
    J Virol; 2024 May; 98(5):e0176223. PubMed ID: 38563762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection.
    Clever S; Limpinsel L; Meyer Zu Natrup C; Schünemann LM; Beythien G; Rosiak M; Hülskötter K; Gregor KM; Tuchel T; Kalodimou G; Freudenstein A; Kumar S; Baumgärtner W; Sutter G; Tscherne A; Volz A
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate.
    Perdiguero B; Marcos-Villar L; López-Bravo M; Sánchez-Cordón PJ; Zamora C; Valverde JR; Sorzano CÓS; Sin L; Álvarez E; Ramos M; Del Val M; Esteban M; Gómez CE
    Front Immunol; 2023; 14():1160065. PubMed ID: 37404819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.
    Tian JH; Patel N; Haupt R; Zhou H; Weston S; Hammond H; Logue J; Portnoff AD; Norton J; Guebre-Xabier M; Zhou B; Jacobson K; Maciejewski S; Khatoon R; Wisniewska M; Moffitt W; Kluepfel-Stahl S; Ekechukwu B; Papin J; Boddapati S; Jason Wong C; Piedra PA; Frieman MB; Massare MJ; Fries L; Bengtsson KL; Stertman L; Ellingsworth L; Glenn G; Smith G
    Nat Commun; 2021 Jan; 12(1):372. PubMed ID: 33446655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.
    Brunet J; Choucha Z; Gransagne M; Tabbal H; Ku M-W; Buchrieser J; Fernandes P; Batalie D; Lopez J; Ma L; Dufour E; Simon E; Hardy D; Petres S; Guinet F; Strick-Marchand H; Monot M; Charneau P; Majlessi L; Duprex WP; Gerke C; Martin A; Escriou N
    J Virol; 2024 May; 98(5):e0169323. PubMed ID: 38563763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.